Search Results
May 27, 2026, 10:11 ET Penguin Ai Adds Product and Commercial Leadership to Match Enterprise Scale
organizations. Purpose-built with domain-specific reasoning, agentic automation, and transparent auditability, Penguin Ai accelerates prior authorization, HCC coding and risk adjustment, claims adjudication, payment integrity, appeals, and other mission-critical processes. Penguin Ai integrates seamlessly with
More news about: Penguin Ai
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).
More news about: Hackensack Meridian John Theurer Cancer Center
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
dose for patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end-stage renal disease.No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate (Child-Pugh
More news about: Eisai Inc.
May 19, 2026, 08:34 ET Helio Genomics Announces Strategic Commercial Partnership with Syneos Health® to Accelerate Nationwide Adoption of HelioLiver™, A Breakthrough AI-Powered Blood Test for Early Liver Cancer Detection
hepatocellular carcinoma (HCC), the most common form of liver cancer. It combines cell-free DNA methylation patterns, protein biomarkers, and patient demographics using a proprietary AI algorithm. In the CLiMB trial – the world's first prospective, blinded, multicenter U.S. study for HCC screening, enrolling
More news about: Helio Genomics
May 18, 2026, 21:35 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
proof-of-concept studies. These cover EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), malignant melanoma, and other areas with high unmet medical needs.Mechanistically,
More news about: Nanjing Leads Biolabs Co., Ltd.
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
activity, safety data, tumor biomarker data and PK data.""Casdozokitug is the only known clinical stage IL-27 antagonist, and the first line HCC study in combination with LOQTORZI is now fully enrolled. We are tracking to initial data around mid-year." said Rosh Dias, MD, Chief Medical Officer.
More news about: Market News Updates
May 08, 2026, 04:17 ET Rznomics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to 'RZ-001' for Hepatocellular Carcinoma
selectivity and safety—presents a promising new option for HCC patients with limited treatment alternatives. RZ-001 previously received Orphan Drug Designation (ODD) in 2024 and Fast Track Designation (FTD) in 2025 for the treatment of HCC.The FDA's decision to grant RMAT status highlights the
More news about: Rznomics
May 06, 2026, 09:20 ET Landmark CLiMB Study Demonstrates Superior Sensitivity of HelioLiver™, a Multi-Analyte Blood Test, Over Ultrasound for Early Detection of Hepatocellular Carcinoma
overall HCC detection (47.8% vs. 28.3%) in this prospective trial, with 60% of the HCC cases at stage I.with even more striking advantages for early-stage and small lesions (37.8% vs. 13.5% for lesions ≤4 cm, and 28.6% vs. 0% for lesions <2 cm), andfor T1/stage 1 HCC (40.0% vs.
More news about: Helio Genomics
May 04, 2026, 08:09 ET Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting
session presenting Phase 1/2 dose-finding data in advanced hepatocellular carcinoma (HCC), which is the third-leading cause of cancer death globally and an area where treatment options remain limited."Advanced HCC is a devastating cancer with limited treatment options, and for the approximately
More news about: Iterion Therapeutics
Apr 21, 2026, 08:00 ET FDA Breakthrough for First Viral-Integration MRD Liquid Biopsy in HCC -- New ctDNA Biomarker Class
95.5% specificitySensitivity superior to AFP alone for tumors <5 cmHCC remains a blind spot in the MRD landscape — no ctDNA MRD platform has yet pursued BDD for liver cancer, despite HCC being the third leading cause of cancer death globally and having >50% five-year recurrence
More news about: TCM Biotech
Apr 20, 2026, 22:10 ET Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile
therapeutic approach for HCC."He added, "Beyond the RZ-001 program, these findings could further support the clinical applicability of our RNA trans-splicing ribozyme platform technology."Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma (HCC) is the most common type of
More news about: Rznomics
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
increased ratio of CD69+/CD3+ T cells in co-cultures of tumor cells and human PBMCs. In vivo, ATG-125 demonstrated sustained antitumor activity in HCC827 xenograft models, increased tumor infiltration of CD4+ and CD8+ T cells in PBMC-humanized models, and inhibited tumor growth in a dose-dependent manner
More news about: Antengene Corporation Limited
Apr 13, 2026, 10:33 ET Badanie DOORwaY90 firmy Sirtex Medical wskazuje na 100% miejscową kontrolę nowotworu przy pomocy SIR-Spheres®, ustanawiając nowy punkt odniesienia w zakresie terapii Y-90 w przypadku nieoperacyjnego raka wątrobowokomórkowego
wątrobę u pacjentów z nieoperacyjnym HCC."Mikrosfery żywiczne SIR-Spheres Y-90 są jedyną terapią radioembolizacyjną zatwierdzoną przez FDA do leczenia zarówno przerzutowego raka jelita grubego do wątroby (mCRC), jak i nieoperacyjnego raka wątrobowokomórkowego (HCC) w Stanach Zjednoczonych.Aby
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
liver-directed therapy for patients with unresectable HCC."SIR-Spheres Y-90 resin microspheres are the only radioembolization therapy approved by the FDA for the treatment of both metastatic colorectal cancer (mCRC) of the liver and unresectable HCC in the U.S.For more information about SIR-Spheres
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
liver-directed therapy for patients with unresectable HCC."SIR-Spheres Y-90 resin microspheres are the only radioembolization therapy approved by the FDA for the treatment of both metastatic colorectal cancer (mCRC) of the liver and unresectable HCC in the U.S.For more information about SIR-Spheres
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Studie DOORwaY90 společnosti Sirtex Medical prokázala stoprocentní lokální kontrolu nádoru pomocí SIR-Spheres® a stanovila tak nový standard v léčbě HCC pomocí Y-90
inoperabilním HCC."Mikrokuličky z pryskyřice SIR-Spheres Y-90 jsou jedinou terapií založenou na radioembolizaci, kterou FDA (Úřad pro kontrolu potravin a léčiv) schválil pro léčbu jak metastatického kolorektálního karcinomu (mCRC) v játrech, tak i neoperovatelného hepatocelulárního karcinomu (HCC) ve Spojených
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Studi DOORwaY90 dari Sirtex Medical Mendemonstrasikan Kontrol Tumor Lokal 100% dengan SIR-Spheres®, Menetapkan Tolok Ukur Baru di Y-90 untuk HCC
terapi yang diarahkan ke hati untuk pasien dengan HCC yang tidak dapat dioperasi."Mikrosfer resin SIR-Spheres Y-90 adalah satu-satunya terapi radioembolisasi yang disetujui oleh FDA untuk pengobatan kanker kolorektal metastatik (mCRC) hati dan HCC yang tidak dapat dioperasi di AS.Untuk informasi
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Die DOORwaY90-Studie von Sirtex Medical belegt eine 100-prozentige lokale Tumorkontrolle mit SIR-Spheres® und setzt damit neue Maßstäbe bei der Y-90-Therapie für HCC
für Patienten mit inoperablem HCC erweitern."Die SIR-Spheres Y-90-Harzmikrosphären sind die einzige von der FDA zugelassene Radioembolisationstherapie zur Behandlung sowohl von metastasiertem kolorektalem Karzinom (mCRC) in der Leber als auch von inoperablem HCC in den USA.Für weitere Informationen
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET El estudio DOORwaY90 de Sirtex Medical demuestra un control tumoral local del 100 % con SIR-Spheres®
para pacientes con carcinoma hepatocelular (HCC) irresectable".Las microesferas de resina SIR-Spheres Y-90 son la única terapia de radioembolización aprobada por la FDA para el tratamiento del cáncer colorrectal metastásico (mCRC) hepático y del HCC irresectable en Estados Unidos.Para obtener
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Štúdia DOORwaY90 spoločnosti Sirtex Medical preukazuje 100 % lokálnu kontrolu nádoru pomocou SIR-Spheres®, čím stanovuje nový štandard pri liečbe Y-90 hepatocelulárneho karcinómu
liečby zameranej na pečeň u pacientov s neresekovateľným HCC."Živicové mikroguličky SIR-Spheres Y-90 sú jedinou rádioembolizačnou terapiou schválenou FDA na liečbu metastatického kolorektálneho karcinómu (mCRC) pečene a neresekovateľného HCC v USA.Viac informácií o SIR-Spheres a pokyny k začleneniu
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Nghiên Cứu DOORwaY90 của Sirtex Medical Chứng Minh Khả Năng Kiểm Soát Khối U Tại Chỗ đạt 100% với SIR-Spheres®, Thiết Lập Chuẩn Mực Mới Trong Điều Trị HCC bằng Y-90
điều trị nhắm vào gan cho bệnh nhân HCC không thể phẫu thuật."Hạt vi cầu nhựa SIR-Spheres Y-90 là liệu pháp xạ trị nội mạch duy nhất được FDA phê duyệt để điều trị cả ung thư đại trực tràng di căn gan (mCRC) và ung thư biểu mô tế bào gan không thể phẫu thuật (HCC) tại Hoa Kỳ.Để biết thêm thông
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET 서텍스 메디컬의 DOORwaY90 시험, SIR-Spheres®로 100% 국소 종양 제어 입증하며 HCC 치료용 Y-90의 새로운 기준 제시
서텍스 메디컬(Sirtex Medical, 이하 '서텍스')이 13일 절제 불가능한 간세포 암종(hepatocellular carcinoma, HCC) 환자를 대상으로 분할 선량측정법(partition dosimetry)을 적용한 Y-90 선택적 체내 방사선 요법(selective internal radiation therapy, SIRT)의 미국 최초 중추적, 전향적, 다기관 임상시험인 DOORwaY90 시험의
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Sirtex Medical 的 DOORwaY90 研究表明，SIR-Spheres® 達成 100% 局部腫瘤控制，為肝細胞癌的 釔-90 療法樹立新基準
[email protected]。關於 SIR-SpheresSIR-Spheres® 釔-90 樹脂微球適用於對無大血管入侵、Child-Pugh A 級肝硬化、肝功能代償良好、身體狀況良好的不可切除肝細胞癌 (HCC) 患者進行局部腫瘤控制。 其亦適用於治療原發性大腸癌的無法切除轉移性肝腫瘤，並可採用 FUDR（氟尿苷）輔助肝內動脈化療 (IHAC) 進行治療。注意：根據美國聯邦法律，本器材只能由醫生或根據醫生的指示出售。 常見副作用包括腹痛、噁心和便秘。 請瀏覽
More news about: Sirtex Medical Inc.
Apr 13, 2026, 08:09 ET Iterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting
where Wnt signaling drives disease."Iterion recently completed a Phase 1 study of tegavivint in patients with advanced hepatocellular carcinoma (HCC), where the therapy demonstrated encouraging clinical responses and durable disease control in heavily pre-treated patients, along with a favorable tolerability
More news about: Iterion Therapeutics
Apr 09, 2026, 20:00 ET Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
vanguard of the global CAR-T race.OriCell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the program is now gearing up for pivotal trials.
More news about: Oricell Therapeutics Holdings Limited